Sarge, you know if we get 50,40,20 cents to a dollar? Lawyers likely will make millions. Raj didn't have to give up a penny. The US is the most F'Ed up system on the planet
Bio have you or anybody here submitted this ? Settlement amount is peanuts compared to the stock price collapse after the guidance was corrected (euphemism). More like 10%
Is this treated as cap gain from tax. Perspective and also this would reduce cap loss carryover, right ?
Nothing. Shanghai gets closer to owning more of taro and his empire gets bigger
Normally share buyback share price incrincrease . In this case not. In fact in the 1st buyback share price went up because they set the floor by buying at higher price. Minority should ask the same for future buybacks
Otherwise what's the point of buyback for minority ?
Raj karma will catch up on you buddy. Don't worry. You sold stock at $12.5 millions of it while issuing this guidance and didn't have to give up any of the money you got by selling your shares at inflated prices. Karma man.
Anyone with more details on this esp tax.
As always Cavejoesherrybaseballgfys et al Please disregard this post.
Cavejoesherrybaseballgfys et al Please disregard this post. Not for you
Anyone here filed claim? Is it easy?
Also tax treatment of this income ? Say I have 10k USD capitall loss carryover from this and I get back 2k USD. Would my capital loss carryover just be reduced to 8k. How do I report this income ?
Don't have any report. With such skimpy info released to public on novexatin, the ATopic dermatitis project they alluded to 2 years ago, how could any analyst put TP.
I assume yahoo tp is from anubhav aggarwal from munbai credit Suisse. As far as I know he is only analyst who has written research reports for taro. Ask him if he has factored recent market data including 2 product loss making derma company sold a few weeks back for $5.2b. Just imagine how much Pfizer would have offered taro if it was on the block ?
What would be your next activist move ? We all know Shanghai has been sitting on taros huge cash for several and finds asset prices too high as taro chairman and, Seemingly finds asset prices ok when working for sun. Also his lieutenant said they may not want to invest in branded asset as taro does not have large sales field force...which I thought was a ludicrous argument for not buying risk mitigated p3 asset like sun is doing. Now sun is going to likely atleast make 30x it's investment in the psoriasis asset imo.
Considering u have pharma background why don't you write to join this board so we can see how Shanghai see asset prices are too high?
Until 90% they can do buyback per my knowledge. There are tons of question on why this product is going at suchslow slow pace . I personally believe it is deliberate..jmho
I also suspect that before the very crucial independent dir elections in Dec they may try to bait shareholders to vote for sun's nominees by trying to release some positive news so share price goes up
I suspect the same...everything is likely tied to their ownership. Early completion of phase 3 or early launch is not in their interest. But a launch in 2023-2024 (vs launch in 2019) could likely significantly increase net worth of someone.
its ridiculous to see that they managed another phase2a from Aug 2013 to now and the data is not even released to public/market. All we know is the data is "encouraging" to Kal and his buddies.
Initially I thought this study had phase2B designation(could be wrong..but that's what I recall). Btw, novobiotics had completed phase2a. Why waste 3 years time to do another phase2a? Wouldn't FDA look at the prior phase2a n allow them to proceed to phase2b?
And even if they wasted 3 years for phase2a, can they now not start phase3
Isnt it their F duty to publish the results and answer the above questions?
Who else believes the pace of development on this is really slow
Phase2a-almost 3 years(aug2013 they got it)
Why was phase2a done when I thought it had completed phase2a already
Why phase2b now? Can they not take it to phase3
Why are they not publishing phase2a results with all shareholders?
Rohan Deuskara. Could still email 6 about this tiny discrepancy in how 2 companies are managed
Num of acquisitions
6month earning call vs 3 month earnings call
many here i have asked for this.
as well one analyst/investor asked for it in the friday's earnings call
Could probably be related to price hike investigation on doxycycline....mylan, endo were all subpeonaed on this and now sun. Just guessing...